Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, Myeloma, VideosDecember 18, 2020
ASH 2020 | Data on Real World Evidence (RWE) on AL amyloidosisAL amyloidosis, ConferencesDecember 10, 2020
MPE webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, MyelomaDecember 8, 2020
ASH 2020 | Certain people with blood cancers and COVID-19 infection vulnerable to severe illnessAL amyloidosis, Conferences, MyelomaDecember 6, 2020
ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, MyelomaDecember 5, 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, MyelomaDecember 5, 2020
